Predictors of outcome in renal vasculitis

Nephrology

Volumn 9, Issue 5, 2004, Pages 254-255

  Jayne, David ^a  

^a ADDENBROOKE S HOSPITAL   (United Kingdom)

Author keywords

[No Author keywords available]

Indexed keywords

AZATHIOPRINE; CORTICOSTEROID; CYCLOPHOSPHAMIDE; IMMUNOGLOBULIN; INFLIXIMAB; MONOCYTE CHEMOTACTIC PROTEIN 1; MYELOBLASTIN; MYELOPEROXIDASE; NEUTROPHIL CYTOPLASMIC ANTIBODY; RITUXIMAB;

CREATININE BLOOD LEVEL; DISEASE MARKER; EARLY DIAGNOSIS; EDITORIAL; GLOMERULONEPHRITIS; HUMAN; INCIDENCE; KIDNEY BIOPSY; KIDNEY DISEASE; KIDNEY FAILURE; KIDNEY FIBROSIS; KIDNEY FUNCTION; MORTALITY; NEUTROPENIA; PRIORITY JOURNAL; PROGNOSIS; PROTEINURIA; REMISSION; RENAL VASCULITIS; SIDE EFFECT; SURVIVAL; TREATMENT OUTCOME; VASCULITIS;

ANTIBODIES, ANTINEUTROPHIL CYTOPLASMIC; HUMANS; KIDNEY; KIDNEY DISEASES; TREATMENT OUTCOME; VASCULITIS;

EID: 9644291535     PISSN: 13205358     EISSN: None     Source Type: Journal    
DOI: 10.1111/j.1440-1797.2004.00326.x     Document Type: Editorial

References (13)

1. Jennette JC, Falk RJ, Andrassy K et al. Nomenclature of systemic vasculitides. Proposal of an international consensus conference. Arthritis Rheum. 1994; 37: 187-92.
2. Watts RA, Scott DG. Classification and epidemiology of the vasculitides. Baillieres Clin. Rheumatol. 1997; 11: 191-217.
3. Booth AD, Almond MK, Burns A et al. Outcome of ANCA-associated renal vasculitis: A 5-year retrospective study. Am. J. Kidney Dis. 2003; 61: 776-84.
4. Jayne D. Current attitudes to the therapy of vasculitis. Kidney Blood Press Res. 2003; 26: 231-9.
5. Jayne D, Rasmussen N, Andrassy K et al. A randomized trial of maintenance therapy for vasculitis associated with antineutrophil cytoplasmic autoantibodies. N. Engl. J. Med. 2003; 349: 36-44.
6. Rasmussen N. European therapeutic trials in ANCA-associated systemic vasculitis: Disease scoring, consensus regimens and proposed clinical trials. Clin. Exp. Immunol. 1995; 101 (Suppl. 1): 29-34.
7. Jayne DR, Rasmussen N. Treatment of antineutrophil cytoplasm autoantibody-associated systemic vasculitis: Initiatives of the European Community Systemic Vasculitis Clinical Trials Study Group. Mayo Clin. Proc. 1997; 72: 737-47.
8. Hauer HA, Bajema IM, van Houwelingen HC et al. Determinants of outcome in ANCA-associated glomerulonephritis: A prospective clinico-histopathological analysis of 96 patients. Kidney Int. 2002; 62: 1732-42.
9. Boomsma MM, Stegeman CA, van der Leij MJ et al. Prediction of relapses in Wegener's granulomatosis by measurement of antineutrophil cytoplasmic antibody levels: A prospective study. Arthritis Rheum. 2000; 43: 2025-33.
10. Gisslen K, Wieslander J, Westberg G, Herlitz H. Relationship between anti-neutrophil cytoplasmic antibody determined with conventional binding and the capture assay, and long-term clinical course in vasculitis. J. Intern. Med. 2002; 251: 129-35.
11. Booth A, Harper L, Hammad T et al. Prospective study of TNFalpha blockade with infliximab in anti-neutrophil cytoplasmic antibody-associated systemic vasculitis. J. Am. Soc. Nephrol. 2004; 15: 717-21.
12. de Groot K, Adu D, Savage C. The value of pulse cyclophosphamide in ANCA-associated vasculitis: Meta-analysis and critical review. Nephrol. Dial. Transplant. 2001; 16: 2018-27.
13. Westman KW, Bygren PG, Olsson H, Ranstam J, Wieslander J. Relapse rate, renal survival, and cancer morbidity in patients with Wegener's granulomatosis or microscopic polyangiitis with renal involvement. J. Am. Soc. Nephrol. 1998; 9: 842-52.